STRUCTURAL AND FUNCTIONAL CARDIAC STATUS AND REMODELING PROCESSES IN PATIENTS WITH TYPE 2 DIABETES MELLITUS RECEIVING SGLT2 INHIBITOR THERAPY

Behruz Tursunaliyev; Asadullo Xabibullayev

Authors

Behruz Tursunaliyev Second-Year Master's Student in Cardiology at Central Asian Medical University Author
Asadullo Xabibullayev Second-Year Master's Student in Cardiology at Central Asian Medical University Author

Keywords:

Type 2 diabetes mellitus, sodium-glucose cotransporter-2 inhibitors, cardiac remodeling, left ventricle, cardiac function

Abstract

This article examines the structural and functional state of the heart and myocardial remodeling processes in patients with type 2 diabetes mellitus receiving sodium-glucose cotransporter-2 inhibitor therapy. Clinical and echocardiographic parameters are used to assess left ventricular structure, myocardial thickness, cardiac function, and remodeling characteristics. The study focuses on the relationship between diabetes-associated metabolic disturbances and cardiac structural and functional changes. The findings emphasize the importance of comprehensive clinical and echocardiographic assessment for evaluating cardiovascular status in patients with type 2 diabetes mellitus receiving sodium-glucose cotransporter-2 inhibitor therapy

Downloads

Download data is not yet available.

References

1. Zinman B., Wanner C., Lachin J. M. [et al.]. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes // New England Journal of Medicine. – 2015. – Vol. 373, No. 22. – P. 2117–2128.

2. Neal B., Perkovic V., Mahaffey K. W. [et al.]. Canagliflozin and cardiovascular and renal events in type 2 diabetes // New England Journal of Medicine. – 2017. – Vol. 377, No. 7. – P. 644–657.

3. Wiviott S. D., Raz I., Bonaca M. P. [et al.]. Dapagliflozin and cardiovascular outcomes in type 2 diabetes // New England Journal of Medicine. – 2019. – Vol. 380, No. 4. – P. 347–357.

4. McMurray J. J. V., Solomon S. D., Inzucchi S. E. [et al.]. Dapagliflozin in patients with heart failure and reduced ejection fraction // New England Journal of Medicine. – 2019. – Vol. 381, No. 21. – P. 1995–2008.

5. Packer M., Anker S. D., Butler J. [et al.]. Cardiovascular and renal outcomes with empagliflozin in heart failure // New England Journal of Medicine. – 2020. – Vol. 383, No. 15. – P. 1413–1424.

6. Anker S. D., Butler J., Filippatos G. [et al.]. Empagliflozin in heart failure with a preserved ejection fraction // New England Journal of Medicine. – 2021. – Vol. 385, No. 16. – P. 1451–1461.

7. Heidenreich P. A., Bozkurt B., Aguilar D. [et al.]. 2022 AHA/ACC/HFSA guideline for the management of heart failure // Circulation. – 2022. – Vol. 145, No. 18. – P. e895–e1032.

8. McDonagh T. A., Metra M., Adamo M. [et al.]. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure // European Heart Journal. – 2021. – Vol. 42, No. 36. – P. 3599–3726.